154 related articles for article (PubMed ID: 35100354)
1. Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms.
Borsani O; Bastard P; Rosain J; Gervais A; Sant'Antonio E; Vanni D; Casetti IC; Pietra D; Trotti C; Catricalà S; Ferretti VV; Malcovati L; Arcaini L; Casanova JL; Borghesi A; Rumi E
Blood; 2022 Apr; 139(17):2716-2720. PubMed ID: 35100354
[No Abstract] [Full Text] [Related]
2. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia.
Slavikova M; Schmeisser H; Kontsekova E; Mateicka F; Borecky L; Kontsek P
J Interferon Cytokine Res; 2003 Mar; 23(3):143-7. PubMed ID: 12716486
[TBL] [Abstract][Full Text] [Related]
3. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency.
Le Voyer T; Parent AV; Liu X; Cederholm A; Gervais A; Rosain J; Nguyen T; Perez Lorenzo M; Rackaityte E; Rinchai D; Zhang P; Bizien L; Hancioglu G; Ghillani-Dalbin P; Charuel JL; Philippot Q; Gueye MS; Maglorius Renkilaraj MRL; Ogishi M; Soudée C; Migaud M; Rozenberg F; Momenilandi M; Riller Q; Imberti L; Delmonte OM; Müller G; Keller B; Orrego J; Franco Gallego WA; Rubin T; Emiroglu M; Parvaneh N; Eriksson D; Aranda-Guillen M; Berrios DI; Vong L; Katelaris CH; Mustillo P; Raedler J; Bohlen J; Bengi Celik J; Astudillo C; Winter S; ; ; McLean C; Guffroy A; DeRisi JL; Yu D; Miller C; Feng Y; Guichard A; Béziat V; Bustamante J; Pan-Hammarström Q; Zhang Y; Rosen LB; Holland SM; Bosticardo M; Kenney H; Castagnoli R; Slade CA; Boztuğ K; Mahlaoui N; Latour S; Abraham RS; Lougaris V; Hauck F; Sediva A; Atschekzei F; Sogkas G; Poli MC; Slatter MA; Palterer B; Keller MD; Pinzon-Charry A; Sullivan A; Droney L; Suan D; Wong M; Kane A; Hu H; Ma C; Grombiříková H; Ciznar P; Dalal I; Aladjidi N; Hie M; Lazaro E; Franco J; Keles S; Malphettes M; Pasquet M; Maccari ME; Meinhardt A; Ikinciogullari A; Shahrooei M; Celmeli F; Frosk P; Goodnow CC; Gray PE; Belot A; Kuehn HS; Rosenzweig SD; Miyara M; Licciardi F; Servettaz A; Barlogis V; Le Guenno G; Herrmann VM; Kuijpers T; Ducoux G; Sarrot-Reynauld F; Schuetz C; Cunningham-Rundles C; Rieux-Laucat F; Tangye SG; Sobacchi C; Doffinger R; Warnatz K; Grimbacher B; Fieschi C; Berteloot L; Bryant VL; Trouillet Assant S; Su H; Neven B; Abel L; Zhang Q; Boisson B; Cobat A; Jouanguy E; Kampe O; Bastard P; Roifman CM; Landegren N; Notarangelo LD; Anderson MS; Casanova JL; Puel A
Nature; 2023 Nov; 623(7988):803-813. PubMed ID: 37938781
[TBL] [Abstract][Full Text] [Related]
5. No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients.
Philippot Q; Bastard P; Puel A; Casanova JL; Cobat A; Laouénan C; Tardivon C; Crestani B; Borie R
Respir Res; 2023 Mar; 24(1):87. PubMed ID: 36941652
[TBL] [Abstract][Full Text] [Related]
6. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.
Meager A; Visvalingam K; Peterson P; Möll K; Murumägi A; Krohn K; Eskelin P; Perheentupa J; Husebye E; Kadota Y; Willcox N
PLoS Med; 2006 Jul; 3(7):e289. PubMed ID: 16784312
[TBL] [Abstract][Full Text] [Related]
7. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19.
Eto S; Nukui Y; Tsumura M; Nakagama Y; Kashimada K; Mizoguchi Y; Utsumi T; Taniguchi M; Sakura F; Noma K; Yoshida Y; Ohshimo S; Nagashima S; Okamoto K; Endo A; Imai K; Kanegane H; Ohnishi H; Hirata S; Sugiyama E; Shime N; Ito M; Ohge H; Kido Y; Bastard P; Casanova JL; Ohara O; Tanaka J; Morio T; Okada S
J Clin Immunol; 2022 Oct; 42(7):1360-1370. PubMed ID: 35764767
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
[TBL] [Abstract][Full Text] [Related]
10. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
[TBL] [Abstract][Full Text] [Related]
11. Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches.
Swaroop A; Saleiro D; Platanias LC
Bioessays; 2023 Mar; 45(3):e2200203. PubMed ID: 36642848
[TBL] [Abstract][Full Text] [Related]
12. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial.
Alotaibi F; Alharbi NK; Rosen LB; Asiri AY; Assiri AM; Balkhy HH; Al Jeraisy M; Mandourah Y; AlJohani S; Al Harbi S; Jokhdar HAA; Deeb AM; Memish ZA; Jose J; Ghazal S; Al Faraj S; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; AlMutairi BM; Al-Dawood A; Abdullah ML; Barhoumi T; Alenazi MW; Almasood A; Holland SM; Arabi YM;
Influenza Other Respir Viruses; 2023 Mar; 17(3):e13116. PubMed ID: 36960162
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against type I IFNs in patients with critical influenza pneumonia.
Zhang Q; Pizzorno A; Miorin L; Bastard P; Gervais A; Le Voyer T; Bizien L; Manry J; Rosain J; Philippot Q; Goavec K; Padey B; Cupic A; Laurent E; Saker K; Vanker M; Särekannu K; ; ; ; ; ; ; ; García-Salum T; Ferres M; Le Corre N; Sánchez-Céspedes J; Balsera-Manzanero M; Carratala J; Retamar-Gentil P; Abelenda-Alonso G; Valiente A; Tiberghien P; Zins M; Debette S; Meyts I; Haerynck F; Castagnoli R; Notarangelo LD; Gonzalez-Granado LI; Dominguez-Pinilla N; Andreakos E; Triantafyllia V; Rodríguez-Gallego C; Solé-Violán J; Ruiz-Hernandez JJ; Rodríguez de Castro F; Ferreres J; Briones M; Wauters J; Vanderbeke L; Feys S; Kuo CY; Lei WT; Ku CL; Tal G; Etzioni A; Hanna S; Fournet T; Casalegno JS; Queromes G; Argaud L; Javouhey E; Rosa-Calatrava M; Cordero E; Aydillo T; Medina RA; Kisand K; Puel A; Jouanguy E; Abel L; Cobat A; Trouillet-Assant S; García-Sastre A; Casanova JL
J Exp Med; 2022 Nov; 219(11):. PubMed ID: 36112363
[TBL] [Abstract][Full Text] [Related]
14. Auto-antibodies against type I IFNs are associated with severe COVID-19 pneumonia.
Zhou W; Wang W
Signal Transduct Target Ther; 2021 Feb; 6(1):96. PubMed ID: 33637681
[No Abstract] [Full Text] [Related]
15. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hematologic diseases with alpha interferon].
Castaigne S
Bull Cancer; 1988; 75(9):859-62. PubMed ID: 3207895
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 mRNA vaccine, but not a viral vector-based vaccine, promotes neutralizing anti-type I interferon autoantibody production in a small group of healthy individuals.
Xu W; Wen X; Cong X; Jiang W
J Med Virol; 2023 Oct; 95(10):e29137. PubMed ID: 37792386
[TBL] [Abstract][Full Text] [Related]
20. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
Gisslinger H; Ludwig H; Linkesch W; Chott A; Fritz E; Radaszkiewicz T
Lancet; 1989 Mar; 1(8639):634-7. PubMed ID: 2564458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
